Tigermed (300347.CN/03347.HK) - Q3 Performance Recovered with Optimistic Future Development
292 Views05 Nov 2020 05:09
This article analyzed Tigermed's business, growth potential, global layout, equity investment and also made forecast and rating for this company.
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 7-minute read)
Related Insights
More »- HK CEO & Director Dealings (8 Feb 2024): Tigermed, East Buy, Kingkey Financial
- China Healthcare Weekly (Dec.25) - Stock Picking Strategy, Logic Flaws Behind a Good Story, Tigermed
- Hangzhou Tigermed Consulting (3347.HK) 23H1 - Performance Inflection Point Has Not yet Arrived
- Hangzhou Tigermed Consulting (3347HK)-Turning Point Emerge, Followed by Sharp Decline in Performance
- China Healthcare Weekly (Jan.13)- Tigermed, HBM, Brii, Jacobio, Dental Implant, Successful Investors
Trending Collections
More »Trending Insights
More »Top Unpaywalled Insights
More »- [IO Technicals 2025/23] Bearish Momentum Persists
- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
- [IO Technicals 2025/22] Bearish Momentum Strengthens
- Texas Power Play: Grid Sovereignty, Bitcoin, and the Future of AI
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Tigermed (300347.CN/03347.HK) - Q3 Performance Recovered with Optimistic Future Development05 Nov 2020
- Jiangsu Hengrui Medicine (600276 CH) - Q3 Performance Improved with Promising Innovative Pipeline28 Oct 2020
- JW Therapeutics - Concerns Are in the Short Term but Still Promising in the Long Term28 Oct 2020
- Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy22 Oct 2020
x